Oramed Pharmaceuticals Net Worth
Oramed Pharmaceuticals Net Worth Breakdown | ORMP |
Oramed Pharmaceuticals Net Worth Analysis
Oramed Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Oramed Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Oramed Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Oramed Pharmaceuticals' net worth analysis. One common approach is to calculate Oramed Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Oramed Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Oramed Pharmaceuticals' net worth. This approach calculates the present value of Oramed Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Oramed Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Oramed Pharmaceuticals' net worth. This involves comparing Oramed Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Oramed Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Oramed Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Oramed Pharmaceuticals' net worth research are outlined below:
| Oramed Pharmaceuticals generated a negative expected return over the last 90 days | |
| Oramed Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.7 M. Net Loss for the year was (37.76 M) with profit before overhead, payroll, taxes, and interest of 2.7 M. | |
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (27.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Reznick Yehuda of 29800 shares of Oramed Pharmaceuticals subject to Rule 16b-3 |
Oramed Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Oramed Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oramed Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Oramed Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oramed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oramed Pharmaceuticals backward and forwards among themselves. Oramed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Oramed Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Qube Research & Technologies | 2023-12-31 | 86.5 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 64.2 K | State Street Corporation | 2023-12-31 | 58 K | Susquehanna International Group, Llp | 2023-12-31 | 45.9 K | Lpl Financial Corp | 2023-12-31 | 43.2 K | Jpmorgan Chase & Co | 2023-12-31 | 28.8 K | Pnc Financial Services Group Inc | 2023-12-31 | 26.2 K | Geode Capital Management, Llc | 2023-12-31 | 25.5 K | American Century Companies Inc | 2023-12-31 | 19.3 K | Murchinson Ltd. | 2023-12-31 | 1.1 M | Bml Capital Management Llc | 2024-03-31 | 844.5 K |
Follow Oramed Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oramed Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Oramed Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Oramed Pharmaceuticals' profitablity
Oramed Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Oramed Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Oramed Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Oramed Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Oramed Pharmaceuticals' profitability requires more research than a typical breakdown of Oramed Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.23) | (0.25) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.22) | (0.24) |
When accessing Oramed Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Oramed Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Oramed Pharmaceuticals' profitability and make more informed investment decisions.
The data published in Oramed Pharmaceuticals' official financial statements usually reflect Oramed Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Oramed Pharmaceuticals. For example, before you start analyzing numbers published by Oramed accountants, it's critical to develop an understanding of what Oramed Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Oramed Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oramed Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Oramed Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oramed Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Oramed Pharmaceuticals' management manipulating its earnings.
Evaluate Oramed Pharmaceuticals' management efficiency
Oramed Pharmaceuticals has return on total asset (ROA) of (0.0516) % which means that it has lost $0.0516 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0324 %, meaning that it created $0.0324 on every $100 dollars invested by stockholders. Oramed Pharmaceuticals' management efficiency ratios could be used to measure how well Oramed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/01/2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.25. At this time, Oramed Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 05/01/2024, Liabilities And Stockholders Equity is likely to grow to about 195.2 M, while Non Current Liabilities Total is likely to drop slightly above 4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.50 | 3.68 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 3.49 | 3.66 | |
| Enterprise Value Over EBITDA | (10.46) | (10.98) | |
| Price Book Value Ratio | 2.78 | 2.92 | |
| Enterprise Value Multiple | (10.46) | (10.98) | |
| Price Fair Value | 2.78 | 2.92 | |
| Enterprise Value | 386.6 M | 405.9 M |
The analysis of Oramed Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Oramed Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Oramed Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 1.353 | Revenue 1.3 M | Quarterly Revenue Growth (1.00) | Revenue Per Share 0.033 | Return On Equity 0.0324 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oramed Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oramed Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oramed Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Reznick Yehuda over a week ago Acquisition by Reznick Yehuda of 29800 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | ||
Reznick Yehuda over three weeks ago Insider Trading | ||
Leonard Sank over three months ago Acquisition by Leonard Sank of 30000 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | ||
Silberman David over six months ago Acquisition by Silberman David of 24500 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | ||
Rozov Yadin over a year ago Acquisition by Rozov Yadin of 30000 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | ||
Rozov Yadin over a year ago Purchase by Rozov Yadin of 20000 shares of Oramed Pharmaceuticals |
Oramed Pharmaceuticals Corporate Filings
F4 | 18th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 2nd of April 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F3 | 22nd of March 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
8K | 19th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Oramed Pharmaceuticals Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Oramed Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Oramed Pharmaceuticals Corporate Directors
Oramed Pharmaceuticals corporate directors refer to members of an Oramed Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Oramed Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Oramed Pharmaceuticals' board members must vote for the resolution. The Oramed Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Roy Eldor | Director | Profile | |
| Avram Hershko | Director | Profile | |
| Ele Ferrannini | Director | Profile | |
| Miriam Kidron | Chief Scientific Officer and Director | Profile |
How to buy Oramed Stock?
The net worth of Oramed Pharmaceuticals is the difference between its total assets and liabilities. Oramed Pharmaceuticals' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Oramed Pharmaceuticals' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Oramed Pharmaceuticals' net worth can be used as a measure of its financial health and stability which can help investors to decide if Oramed Pharmaceuticals is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Oramed Pharmaceuticals stock.Already Invested in Oramed Pharmaceuticals?
The danger of trading Oramed Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Oramed Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Oramed Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Oramed Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Oramed Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Oramed Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Oramed Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Oramed Pharmaceuticals Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Oramed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oramed Pharmaceuticals. If investors know Oramed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oramed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.14 | Revenue Per Share 0.033 | Quarterly Revenue Growth (1.00) | Return On Assets (0.05) | Return On Equity 0.0324 |
The market value of Oramed Pharmaceuticals is measured differently than its book value, which is the value of Oramed that is recorded on the company's balance sheet. Investors also form their own opinion of Oramed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oramed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oramed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oramed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oramed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oramed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.